Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
People who work in pharmaceutical chemistry run into specialty materials almost every day, and (2R,3R,4R,5R)-5-(Benzamido-2-Oxopyrimidin-1(2H)-Yl)-2-(Benzoyloxymethyl)-4-Fluoro-4-Methyltetrahydrofuran-3-Yl BP EP USP Pharma Grade is about as specialized as molecules get. At its core, you’re looking at a pyrimidine-based compound with modifications that introduce benzamido, benzoyloxymethyl, fluoro, and methyl groups, all perched on a tetrahydrofuran scaffold. That molecular backbone usually speaks to its complexity, the skills needed to synthesize it, and the tighter controls people in the supply chain must follow. You’ll spot it under the “BP EP USP” pharma specifications, pointing out that not only do European and British Pharmacopoeia approve it, the United States Pharmacopoeia recognizes its grade and purity as well. When products reach this level, researchers and drug developers can move with confidence—you already know the standards backing them.
To someone who has slogged through hours drawing chemical structures by hand, this compound’s elegance stands out. The attached benzamido and benzoyloxymethyl groups affect solubility and stability, while the fluorine on the tetrahydrofuran ring modifies reactivity and sometimes bioavailability. The IUPAC name tends to trip folks up, but the underlying chemistry is worth it: the molecular formula sometimes goes as C22H20FN3O6 for solid reference. For international shippers, customs officials, and regulatory agencies, the HS Code clarifies everything—pharmaceutical intermediates like this one land in specific HS Code categories based on their intended application, making documentation smoother for cross-border movement and helping trace each batch back to a raw material origin. Getting the HS Code right ensures you’re following both international and domestic transport and safety rules, with no delays due to misclassified or ambiguously labeled materials.
Anyone working in a lab starts to care a lot about how chemical substances arrive. Product form isn’t a footnote—it shapes safety protocols, measurement, and storage. This compound often comes as a white to off-white powder or crystalline solid, depending on manufacturing runs and purification. Its density usually runs close to 1.45–1.60 g/cm³, so users need accurate balances and sometimes humidity control. Folks handling it in kilograms or larger volumes quickly see why manufacturers offer it as powder, granules, or sometimes flakes—each form serves a different process, from direct tableting to further dissolution for synthesis. Its melting point lands in the 170–180°C region, making it stable in moderate temperatures but sensitive under direct flame or overheating. Given that it’s a pharma-grade material, even its particle size distribution, flow, and dusting characteristics draw careful documentation, because any mishandling could compromise a finished drug product. Some suppliers offer it dissolved in specific solvents, creating liquid or solution forms for folks wanting faster mixing or more precise dosing during chemical transformations. Pearls or pellets aren’t as common here, but some upstream intermediates share these features, so keeping an eye on incoming raw materials offers a safety net against laboratory accident or contamination.
Every time I open a drum or break a seal on a new batch, Material Safety Data Sheets become my best friend. With benzamido and fluoro groups, you expect some degree of reactivity or even toxicity. This compound is generally non-volatile, but its ability to irritate mucous membranes and skin means gloves, goggles, and low-dust handling systems become routine. The benzamido and benzoyloxymethyl groups rarely make materials inert—always double-check compatibility with storage plastics, seals, or other chemicals. Accidental inhalation or ingestion shouldn’t be brushed off. I saw a tech miss PPE one day, which earned them a trip to the nurse. Pharma-grade doesn’t mean risk-free. Chemical property sheets rate it as “harmful if swallowed or inhaled,” so chemical fume hoods and proper respirator masks step up from “nice to have” to required. A decent safety culture insists on clear labelling, locked storage, and emergency spill kits nearby. Old-school safety rules still win: no eating or drinking in the lab, regular safety audits, and clear workflows from store to bench and back again. Categorizing as “hazardous” keeps logistics teams alert, so shipping boxes and manifests announce its presence everywhere from customs to final destination. Each point in the chain follows compliance strictly, whether they’re filling tiny vials or bulk containers heading overseas. No one wants a simple paperwork error turning into a shipment seized at the border.
From the chemical engineer’s point of view, nothing stands alone in the pipeline. This compound regularly acts as a starting point or intermediate, particularly in making anti-viral or anti-cancer agents where modified nucleoside analogues pop up. The fluoro and benzamido additions often boost biological activity or stability in ways you don’t get with simpler, unmodified analogues. As a raw material, its purity speaks volumes—downstream products demand tight control over trace metals, water, and residual solvents. Failure at this point ripples out, dragging quality problems through finished products. Having seen batches rejected for minute levels of impurities, I know why so much attention falls on documentation and full analytical panels: NMR, HPLC, and mass spec numbers for every lot, sometimes stretching into multi-page reports. In regulated pharmaceutical manufacturing, using just any supplier isn’t an option; audits, site visits, and certification checks all become routine.
Buyers and regulatory authorities agree on one thing: transparency in product specifications keeps supply, quality, and safety on target. This pharma grade, carrying BP, EP, USP tags, needs documentation for identity, strength, purity, and uniformity. Typical specs outline identity by TLC or HPLC, color, water content (by Karl Fischer analysis), melting point, particle size, and a complete impurity profile. Only a handful of manufacturers regularly meet these standards, because analytical equipment and skilled chemists don’t come cheap. Specifications form the foundation for batch release, import/export, and pharmacovigilance—get those specs wrong and patient safety drops fast. Batch numbers, COAs (Certificates of Analysis), and full traceability from incoming raw materials all flow into the compliance machine, let alone the regulatory filings and manufacturing records for finished drugs. Every spec sheet also details shelf life, recommended storage (cool, dry, well-sealed), and any specific incompatibilities (like strong oxidizers or acids). Without nailing these details, recalls or regulatory sanctions move from theory to reality.
The industry’s pressure for lower cost, higher purity, and rapid delivery never takes a break. Sourcing teams hunt relentlessly for reliable suppliers with validated synthesis routes who hold certifications and a clean regulatory record. My experience with sudden contaminant spikes—it takes months to resolve—means I check suppliers against the most current standards and push for shared technical data before closing any deal. Over time, advances in solid-phase synthesis, greener solvents, and continuous flow chemistry promise safer, more efficient manufacturing processes. Companies investing in automation, advanced analytics, and digital inventory see fewer mistakes, quicker recalls, and smoother audits. Cross-company data sharing and proper chain of custody close gaps that once led to mystery contamination or containers arriving with the wrong certificate. If I’ve learned anything, it’s that details in raw materials link directly to patient outcomes. Maintaining high integrity in raw material choices, safety protocols, and full documentation keep the gears of pharma running—no shortcut replaces experience and constant vigilance at every step from bench to bedside.
Chengguan District, Lanzhou, Gansu, China
